Eisai's epilepsy drug Zonegran appears to put patients at higher risk of metabolic acidosis, a chemical imbalance that can lead to heart arrhythmia, breathing difficulties and fatigue, the FDA warned. Recent reports of the side effects prompted the agency to recommend that doctors monitor blood serum levels in patients taking the drug. An Eisai spokeswoman said the company submitted a proposed label change to the FDA.

Full Story:
The Seattle Times

Related Summaries